Infectech, Inc. (Pink Sheets:IFEC - News) has received third party verification of its technology by Dr. Paul Hyman of Ohio State University.
September 18, 2004 (Press Release) --
BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Sept. 7, 2004--Nutra Pharma Corp. (OTCBB:NPHC - News), a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced today that its majority owned subsidiary, Infectech, Inc. (Pink Sheets:IFEC - News) has received third party verification of its technology by Dr. Paul Hyman of Ohio State University. Dr. Hyman has achieved the identification and bacterial genetic amplification of an important strain of Mycobacteria faster than what is presently in the medical literature.
"Mycobacterium avium paratuberculosis could be detected significantly sooner than expected for normal culture techniques," stated Professor Hyman. "The bacterium are slow-growing and can take longer than fourteen weeks to culture using the current accepted media. With Infectech's technology, sufficient DNA for PCR gene amplification could be extracted from paraffin that had no visible colonies on it, sometimes in as little as one week," he concluded.
"Mycobacterium avium paratuberculosis could be detected significantly sooner than expected for normal culture techniques," stated Professor Hyman. "The bacterium are slow-growing and can take longer than fourteen weeks to culture using the current accepted media. With Infectech's technology, sufficient DNA for PCR gene amplification could be extracted from paraffin that had no visible colonies on it, sometimes in as little as one week," he concluded.
Email
Print
SPAM
LEAVE A COMMENT
